Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles


Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine

Richard P Baum, Harshad R Kulkarni

Citation Information : Baum RP, Kulkarni HR. Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine. J Postgrad Med Edu Res 2013; 47 (1):47-53.

DOI: 10.5005/jp-journals-10028-1055

Published Online: 01-12-2014

Copyright Statement:  Copyright © 2013; The Author(s).


How to cite this article

Kulkarni HR, Baum RP. Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine. J Postgrad Med Edu Res 2013; 47(1):47-53.

PDF Share
  1. Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012;42:190-207.
  2. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33;652-58.
  3. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: On the way to theranostics. Dalton Trans 2011;40:6104-11.
  4. WAP A simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem 2012;23:1712-17.
  5. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyrc3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med Mol Imaging 1997;24: 368-71.
  6. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-18.
  7. [177Lu-DOTAOTyr3] octreotate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
  8. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumours: Characterization of uptake in normal organs and tumour lesions. Q J Nucl Med Mol Imag 2010;54:61-67.
  9. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011;52:1412-17.
  10. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med Mol Imag 1993;20:716-31.
  11. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumours: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41: 1114-19.
  12. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: Preliminary data. Eur J Nucl Med Mol Imaging 2001;28:1751-57.
  13. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
  14. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;8:1659-68.
  15. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010;37:67-77.
  16. Standardized uptake values of 68Ga-DOTANOC PET: A promising prognostic tool in neuroendocrine tumours. J Nucl Med 2010;51:353-59.
  17. Functional imaging of neuroendocrine tumours with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-55.
  18. Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging? Hell J Nucl Med 2009;12:102-05.
  19. PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: First human study. Eur J Nucl Med Mol Imag 2010;37:834
  20. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison. J Pept Sci 2011;17:405-12.
  21. 68Galabeled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010;37:1345-55.
  22. Exendin-4-based radiopharmaceuticals for glucagon like peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010;51:1059-67.
  23. 68Ga- and 111In-labeled DOTARGD peptides for imaging of alphav beta3 integrin expression. Eur J Nucl Med Mol Imaging 2008;35:1507-15.
  24. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 2011;52:1803-10.
  25. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogs. Eur J Nucl Med Mol Imaging 2010; 37:1386-96.
  26. Ventilation/perfusion scans using Ga-68 labeled tracers. World J Nucl Med 2011;10:26-59.
  27. A gallium-labeled DOTAalpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004; 45:116-23.
  28. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111Inor 68Ga-labeled affibody molecules. J Nucl Med 2010;51: 892-97.
  29. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumour-host interactions? Int J Cancer 1994;56:681-88.
  30. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
  31. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-23.
  32. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumour. World J Gastroenterol 2009;15:5867-70.
  33. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTANOC. Cancer Biother Radiopharm 2007;22:406-16.
  34. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem 2011;105:313-20.
  35. Postelution processing of (44)Ti/ (44)Sc generator-derived (44)Sc for clinical application. Appl Radiat Isot. 2010;68:1636-41.
  36. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46:83-91.
  37. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62-66.
  38. Theranostics: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-The Bad Berka experience. Theranostics 2012;2:437-47
  39. First clinical experience using 177Lu-BPAMD for the treatment of skeletal metastases in prostate cancer (Abstract). Eur J Nucl Med Mol Imaging 2011;38:225
  40. Radiolabeled GRPR-antagonists: New promising tools in the diagnosis and therapy of GRPR positive tumours (Abstract). World J Nucl Med 2011;10:26-59.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.